LifeSciencesWorld

Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream

Wed, 19 Nov 2008 20:15:00 -0500

[NEWS] Study did not achieve statistical significance ISELIN, N.J., Nov. 19/PRNewswire-FirstCall/ — Pharmos Corporation (Nasdaq: PARS) today announced results from its Phase 2a clinical trial of its topical NanoEmulsion (NE) drug delivery technology formulated with 3% Diclofenac Diethanolamine. The multi-center, randomized, double-…

SyntheMed Announces FDA Clearance of SinusShield(TM)

Wed, 19 Nov 2008 20:00:00 -0500

[NEWS] ISELIN, N.J., Nov. 19 /PRNewswire-FirstCall/ — SyntheMed, Inc. (OTC Bulletin Board: SYMD) announced today that it has received FDA 510(k) clearance to market SinusShield™, a bioresorbable membrane intended to prevent post-operative adhesions in nasal and sinus surgical procedures. There are approximately two million nasal and sinus procedures performed annually in the United States. Robert P. Hickey, SyntheMed's President & CEO stated, “SinusShield represents an…

New Insight Into the Controls on a Go-To Enzyme

Wed, 19 Nov 2008 19:23:00 -0500

[NEWS] St. Jude scientists report basic findings on critical enzyme's regulation may hold key to understanding how to better treat an array of disorders MEMPHIS, Tenn., Nov. 19 /PRNewswire-USNewswire/ —Scientists at St. Jude Children's Research Hospital have gained new insights into regulation of one of the body's enzyme workhorses called calpains. As the cell's molecular overachievers, calpains function in many cellular processes, including th…

GEN Reports on the Trend Toward Predictive Toxicogenomics

Wed, 19 Nov 2008 15:55:00 -0500

[NEWS] NEW ROCHELLE, N.Y., Nov. 19 /PRNewswire/ — Biotech scientists increasingly are applying genomics technologies to toxicology research to better understand the effects of novel drug candidates on a variety of organ systems, reports Genetic Engineering & Biotechnology News (GEN). They are especially interested in figuring out a new compound's mechanism of action and eventually developing a predictive toxicology technique, according to the November 15 issue of GEN. (<a hre…

Par Pharmaceutical Begins Shipment of Budesonide Inhalation Suspension Immediately

Wed, 19 Nov 2008 15:48:00 -0500

[NEWS] WOODCLIFF LAKE, N.J., Nov. 19 /PRNewswire-FirstCall/ — Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it has entered into a supply and distribution agreement with AstraZeneca in the U.S. to market budesonide inhalation suspension, which is a generic form of AstraZeneca's Pulmicort Respules® indicated for the maintenance treatment of asthma. Par began shipping 0.25 mg/2 ml and 0….

PharmAthene Signs Agreement with Medison Pharma Ltd. ...

Wed, 19 Nov 2008 14:00:00 -0500

[NEWS] ANNAPOLIS, Md., Nov. 19 /PRNewswire-FirstCall/ — PharmAthene, Inc. (NYSE Alternext US: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it has signed an agreement with Medison Pharma Ltd., to commercialize its biodefense products in Israel. “The need for advanced medical countermeasures to combat the risk of terrorist attacks with biological or chemical weapons is a significant global concern,” stated David…

ChinaBio(R) Inaugural Partnering Forum Scheduled for June 2009 in Shanghai, China

Wed, 19 Nov 2008 12:30:00 -0500

[NEWS] SHANGHAI, China, Nov. 19 /PRNewswire/ — ChinaBio® Accelerator today announced it is organizing the first partnering forum focused on China life science technology to be held in China. The ChinaBio® Partnering Forum, scheduled for June 3 and 4, 2009 in Shanghai, will bring together more than 300 attendees seeking to enter into partnership deals. The two-day forum will feature one-on-one partnering meetings, technology presentations by China-based researchers and biotech companies, big pharma leader…

Uptake of Next-Generation Antifungals Has Intensified Competition in the Severe Fungal ...

Wed, 19 Nov 2008 12:00:00 -0500

[NEWS] However, Generic Erosion and a Dearth of Promising Emerging Therapies Will Result in Modest Annual Growth, According to a New Report from Decision Resources WALTHAM, Mass., Nov. 19 /PRNewswire/ — Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to their improvements in safety and efficacy, physicians are increasingly prescribing next-generation antifungals such as Pfizer&#3…

Isogen Launches Major New Facility to Address Global Biopharma Demand

Wed, 19 Nov 2008 11:00:00 -0500

[NEWS] NEWARK, Del., Nov. 19 /PRNewswire/ — Isogen, a contract development and manufacturing organization for sterile filling, today announced the first phase launch of its contract facility in Delaware. Isogen was founded to specifically address the process, facility and capacity problems commonly associated with the $2 billion highly-niched, low-volume clinical and early-stage commercial sterile filling market segment. Companies can invest over $100 million and four years to develop sterile manu…

Growing Demand for High-Quality and Cost-Effective Imaging Equipment in Life Sciences

Wed, 19 Nov 2008 09:00:00 -0500

[NEWS] LONDON, Nov. 19 /PRNewswire/ — There are considerable opportunities for imaging systems in the European life sciences industry. However, imaging modalities vendors should focus primarily on providing cost-benefits to users by offering the best package of technology, quality and customer value. Vendors with such a combination will be able to successfully capture the market. (Logo: http://www.newscom.com/cgi-bin/prnh…

Early Career Scientists and Engineers: Computational Biochemistry Research Group

Thu, 23 Oct 2008 10:54:07 -0500

[JOB] D. E. Shaw Research, New York, New York, United States D. E. Shaw Research (“DESRES”) is an independent research laboratory that conducts basic scientific research in the field of computational biochemistry under the direct scientific leadership of Dr. David Shaw, who serves as its Chief Scientist.

Marketing Manager

Tue, 16 Sep 2008 23:38:43 -0500

[JOB] Burrill & Company, San Francisco, CA, United States San Francisco-based Media Group in requires Marketing Manager. We have several events and publications with an executive-level, global audience in the Life Sciences/Financial Industries.

Scientific Asset Services Service Engineer

Tue, 02 Sep 2008 15:03:31 -0500

[JOB] GE Healthcare, Radnor, PA, United States Reporting to the Scientific Asset Services (SAS) Site Lead, the SAS Service Engineer will diagnose, repair, and maintain designated GE Healthcare and OEM instrumentation within the scope of the SAS agreement. He/She represents GE Healthcare at the custome

clinical pharmacokineticist

Mon, 17 Nov 2008 21:45:07 -0500

[JOB] Drug development biotechnology company in Boston, Boston, MA, USA

Study Director Toxicology

Mon, 17 Nov 2008 19:47:57 -0500